P&K Skin Research Center (347740): Korean Industrials stock

What the company does

P&K Skin Research Center runs a clinical testing laboratory that measures whether cosmetics, beauty devices, and health supplements actually do what their makers claim, running both human-subject trials and lab-based tests.

Its clients are domestic and international manufacturers and distributors of cosmetics, beauty devices, and health functional foods. Listed on KOSDAQ, Korea's tech and small-cap board, the company earns the large majority of its revenue from cosmetic human-application trials, with other human trials and lab tests making up the remainder.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$16.5M

▲ +27.7% YoY

Operating profit · FY2025

US$2.9M

▲ +52.6% YoY

Net income · FY2025

US$3.3M

▼ −19.2% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$10.8M(₩14.8B)	US$12.9M(₩17.8B)	US$16.5M(₩22.8B)
Operating profit	US$999.2K(₩1.4B)	US$1.9M(₩2.6B)	US$2.9M(₩3.9B)
Net income	US$3.4M(₩4.7B)	US$4.1M(₩5.7B)	US$3.3M(₩4.6B)

Revenue

FY2023US$10.8M
FY2024US$12.9M
FY2025US$16.5M

Operating profit

FY2023US$999.2K
FY2024US$1.9M
FY2025US$2.9M

Net income

FY2023US$3.4M
FY2024US$4.1M
FY2025US$3.3M

Key ratios (FY2025)

ROE

5.7%

Debt/Eq

7.5%

Op. margin

17.3%

Net margin

20.2%

Rev. YoY

▲ +27.7%

Why it matters · Context, not a recommendation

Korean regulations require cosmetics makers to obtain certified efficacy evidence from the Ministry of Food and Drug Safety before making functional claims, which underpins demand for third-party testing services like those P&K provides.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?